New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
08:37 EDTADMSAdamas Pharmaceuticals presents positive results from ADS-5102 study
Adamas Pharmaceuticals presented data on the rater and subject training process utilized in the Phase 2/3 EASED safety and efficacy study of ADS-5102 for the treatment of levodopa-induced dyskinesia, a condition characterized by involuntary movements without purpose that can become severely disabling, rendering individuals with Parkinson's disease unable to perform routine daily tasks. The Phase 2/3 EASED study met its primary endpoint and the efficacy results of ADS-5102 were aligned across all outcome measures. In addition, ADS-5102 was generally well tolerated with reported adverse events consistent with Parkinson's disease and the known amantadine safety profile.
News For ADMS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 12, 2015
16:04 EDTADMSAdamas reports nonclinical findings on ADS-5102 for multiple sclerosis
Adamas Pharmaceuticals announced findings from two nonclinical studies that demonstrate the potential of ADS-5102 for the treatment of multiple sclerosis symptoms. Researchers conducted nonclinical studies designed to evaluate the efficacy of amantadine for the treatment of MS-related symptoms, including walking impairment, using in vivo models of MS and to better understand the mechanisms of action of amantadine in MS. Data demonstrated that in models of MS, chronic administration of amantadine at a dose intended to match the human plasma levels of ADS-5102 improved walking. Additionally, data from an in vitro study demonstrated that amantadine blocked neuronal potassium channel activity, which may result in enhanced electrical impulses across demyelinated regions of neurons, the company said. Adamas noted that it expects top-line results from its Phase 2 clinical trial of ADS-5102 in 2016.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use